Rosuvastatin Rosuvastatin rosuvastatin R Ro Ros Rosu BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 no 0 10 0 0 0 0 1
Rosuvastatin calcium rosuvastatin R Ro Ros Rosu BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 no 0 10 0 0 0 0 1
Jeremy Quirk, jeremy J Je Jer Jere BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 1 INITCAP NODIGIT 0 1 0 0 0 0 0 0 0 0 , 1 10 0 0 0 0 1
FRESH FROM fresh F FR FRE FRES BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 10 0 0 0 0 0
N E n N N N N BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 0 0 no 0 10 0 0 0 0 0
NATURE REVIEWS nature N NA NAT NATU BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 10 0 0 0 0 0
VOLUME 2 volume V VO VOL VOLU BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 10 0 0 0 0 0
Rosuvastatin calcium rosuvastatin R Ro Ros Rosu BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 (;), 4 9 0 0 0 0 1
the seventh the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 , 1 8 0 0 0 0 1
approved by approved a ap app appr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 8 0 0 0 0 1
the reduction the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 10 0 0 0 0 1
with hypercholesterolaemia. with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 . 1 8 0 0 0 0 1
most potent most m mo mos most BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 , 1 9 0 0 0 0 1
initial setbacks initial i in ini init BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 9 0 0 0 0 1
in the in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 0 0 -- 2 8 0 0 0 0 1
cholesterol-lowering drugs? cholesterol-lowering c ch cho chol BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 -? 2 5 0 0 0 0 1
Epidemiological studies epidemiological E Ep Epi Epid BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 1 -- 2 9 0 0 0 0 1
cal trials cal c ca cal cal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 0 1 - 1 9 0 0 0 0 1
lowering drugs lowering l lo low lowe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 no 0 8 0 0 0 0 1
association between association a as ass asso BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 - 1 8 0 0 0 0 1
density-lipoprotein cholesterol density-lipoprotein d de den dens BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 1 -(-) 4 8 0 0 0 0 1
decreased morbidity decreased d de dec decr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 - 1 8 0 0 0 0 1
nary heart nary n na nar nary BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 1 ()–. 4 9 0 0 0 0 1
demonstrated benefits demonstrated d de dem demo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 - 1 8 0 0 0 0 1
levels, many levels, l le lev leve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 ,- 2 8 0 0 0 0 1
lowering therapies lowering l lo low lowe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 - 1 10 0 0 0 0 1
recommended by recommended r re rec reco BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 . 1 8 0 0 0 0 1
need for need n ne nee need BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 - 1 9 0 0 0 0 1
has encouraged has h ha has has BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 no 0 9 0 0 0 0 1
of established of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 , 1 8 0 0 0 0 1
efforts to efforts e ef eff effo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 no 0 8 0 0 0 0 1
drugs with drugs d dr dru drug BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 no 0 9 0 0 0 0 1
used to used u us use used BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 - 1 8 0 0 0 0 1
levels in levels l le lev leve BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 . 1 8 0 0 0 0 1
Therapeutic hypothesis therapeutic T Th The Ther BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 2 no 0 10 0 0 0 0 1
Statins inhibit statins S St Sta Stat BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 2 --- 3 7 0 0 0 0 1
methylglutaryl CoA methylglutaryl m me met meth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 2 (-), 4 7 0 0 0 0 1
which catalyses which w wh whi whic BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 - 1 8 0 0 0 0 1
mevalonate, an mevalonate, m me mev meva BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 2 ,- 2 9 0 0 0 0 1
cholesterol biosynthesis cholesterol c ch cho chol BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 . 1 10 0 0 0 0 1
to reductions to t to to to BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 - 1 8 0 0 0 0 1
mechanisms: first, mechanisms: m me mec mech BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 :, 2 8 0 0 0 0 1
mevalonate levels, mevalonate m me mev meva BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 2 , 1 9 0 0 0 0 1
in the in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 2 , 1 8 0 0 0 0 1
upregulation of upregulation u up upr upre BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 2 no 0 8 0 0 0 0 1
that mediate that t th tha that BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 - 1 8 0 0 0 0 1
plasma; and plasma; p pl pla plas BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 ;, 2 8 0 0 0 0 1
hepatic synthesis hepatic h he hep hepa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 2 --- 3 8 0 0 0 0 1
protein (VLDL), protein p pr pro prot BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 (),-. 5 8 0 0 0 0 1
Statins also statins S St Sta Stat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 2 no 0 8 0 0 0 0 1
(increased levels (increased ( (i (in (inc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 2 ( 1 10 0 0 0 0 1
CHD) and chd) C CH CHD CHD) BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 2 )-- 3 8 0 0 0 0 1
lipoprotein cholesterol lipoprotein l li lip lipo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 2 (-, 3 8 0 0 0 0 1
levels of levels l le lev leve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 ). 2 8 0 0 0 0 1
The first the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 2 ,(;), 5 9 0 0 0 0 1
was marketed was w wa was was BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 , 1 8 0 0 0 0 1
joined by joined j jo joi join BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 (;),- 5 9 0 0 0 0 1
tatin (Pravachol; tatin t ta tat tati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 2 (;-),- 6 9 0 0 0 0 1
tatin (Lescol; tatin t ta tat tati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 2 (;),(; 6 10 0 0 0 0 1
Pfizer), and pfizer), P Pf Pfi Pfiz BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 2 ),(;), 6 8 0 0 0 0 1
although cerivastatin although a al alt alth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 no 0 8 0 0 0 0 1
the market the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 no 0 9 0 0 0 0 1
of reported of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 ( 1 8 0 0 0 0 1
muscular toxicity), muscular m mu mus musc BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 2 ),. 3 9 0 0 0 0 1
Drug properties drug D Dr Dru Drug BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 4 no 0 10 0 0 0 0 1
Rosuvastatin calcium rosuvastatin R Ro Ros Rosu BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 4 (.) 3 8 0 0 0 0 1
through the through t th thr thro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 no 0 9 0 0 0 0 1
of pyrimidine-substituted of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 -,--- 5 8 0 0 0 0 1
heptenoates containing heptenoates h he hep hept BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 4 no 0 8 0 0 0 0 1
introduced to introduced i in int intr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 no 0 9 0 0 0 0 1
improve selectivity improve i im imp impr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 ., 2 10 0 0 0 0 1
lower lipophilicity lower l lo low lowe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 no 0 8 0 0 0 0 1
reduced metabolism reduced r re red redu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 . 1 7 0 0 0 0 1
Unlike a unlike U Un Unl Unli BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 4 , 1 9 0 0 0 0 1
calcium is calcium c ca cal calc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 4 no 0 8 0 0 0 0 1
cytochrome P450 cytochrome c cy cyt cyto BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 4 , 1 8 0 0 0 0 1
P450 involved p450 P P4 P45 P450 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 5 , 1 9 0 0 0 0 1
less potential less l le les less BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 –. 2 8 0 0 0 0 1
Rosuvastatin calcium rosuvastatin R Ro Ros Rosu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 5 no 0 8 0 0 0 0 1
potent than potent p po pot pote BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 ,- 2 9 0 0 0 0 1
tatin in tatin t ta tat tati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 5 -, 2 10 0 0 0 0 1
and more and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 no 0 9 0 0 0 0 1
plasma LDL-levels plasma p pl pla plas BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 -, 2 9 0 0 0 0 1
chosen for chosen c ch cho chos BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 5 . 1 6 0 0 0 0 1
Clinical data clinical C Cl Cli Clin BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 6 no 0 10 0 0 0 0 1
In a in I In In In BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 2 6 -,-,-, 6 9 0 0 0 0 1
study in study s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 , 1 9 0 0 0 0 1
single daily single s si sin sing BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 (,,) 4 9 0 0 0 0 1
of rosuvastatin of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 no 0 8 0 0 0 0 1
levels of levels l le lev leve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 -,-,-- 6 7 0 0 0 0 1
apolipoprotein B apolipoprotein a ap apo apol BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 6 (, 2 8 0 0 0 0 1
consituent of consituent c co con cons BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 6 ). 2 8 0 0 0 0 1
Rosuvastatin calcium rosuvastatin R Ro Ros Rosu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 6 no 0 7 0 0 0 0 1
three other three t th thr thre BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 -- 2 9 0 0 0 0 1
ing 2,240 ing i in ing ing BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 2 6 ,- 2 9 0 0 0 0 1
cholesterolaemia. After cholesterolaemia. c ch cho chol BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 6 ., 2 9 0 0 0 0 1
were treated were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 no 0 10 0 0 0 0 1
of either of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 (, 2 9 0 0 0 0 1
40 mg), 40 4 40 40 40 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 2 6 ),(,, 5 9 0 0 0 0 1
mg), pravastatin mg), m mg mg) mg), BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 6 ),(,) 5 8 0 0 0 0 1
simvastatin (10 simvastatin s si sim simv BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 6 (,,); 5 9 0 0 0 0 1
size of size s si siz size BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 no 0 7 0 0 0 0 1
156–167 patients 156–167 1 15 156 156– BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 6 –.-,- 5 9 0 0 0 0 1
tatin calcium tatin t ta tat tati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 6 -,- 3 9 0 0 0 0 1
nificantly more nificantly n ni nif nifi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 6 (), 3 9 0 0 0 0 1
simvastatin 10–40 simvastatin s si sim simv BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 6 –(–)- 5 7 0 0 0 0 1
tatin 10–40 tatin t ta tat tati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 6 –(–)., 6 9 0 0 0 0 1
rosuvastatin calcium rosuvastatin r ro ros rosu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 6 - 1 7 0 0 0 0 1
levels by levels l le lev leve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 , 1 9 0 0 0 0 1
80 mg 80 8 80 80 80 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 2 6 . 1 7 0 0 0 0 1
Indications Indications indications I In Ind Indi BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 8 no 0 10 0 0 0 0 1
Rosuvastatin calcium rosuvastatin R Ro Ros Rosu BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 8 no 0 9 0 0 0 0 1
to diet to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 8 -,-, 4 9 0 0 0 0 1
B, non-HDL-C b, B B, B, B, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 8 ,--, 4 9 0 0 0 0 1
increase levels increase i in inc incr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 8 - 1 8 0 0 0 0 1
primary hypercholesterolaemia primary p pr pri prim BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 8 ( 1 8 0 0 0 0 1
familial and familial f fa fam fami BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 8 -)- 3 9 0 0 0 0 1
daemia (Frederickson daemia d da dae daem BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 8 (). 3 8 0 0 0 0 1
On the on O On On On BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 8 -,- 3 8 0 0 0 0 1
tatin calcium tatin t ta tat tati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 8 no 0 10 0 0 0 0 1
diet for diet d di die diet BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 8 no 0 10 0 0 0 0 1
serum triglyceride serum s se ser seru BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 8 ( 1 9 0 0 0 0 1
IV) and iv) I IV IV) IV) BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 8 )-,- 4 9 0 0 0 0 1
Apo B apo A Ap Apo Apo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 8 no 0 8 0 0 0 0 1
hypercholesterolaemia as hypercholesterolaemia h hy hyp hype BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 8 no 0 9 0 0 0 0 1
lipid-lowering treatments lipid-lowering l li lip lipi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 8 - 1 9 0 0 0 0 1
are unavailable are a ar are are BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 8 . 1 4 0 0 0 0 1
▲ ▲ ▲ ▲ ▲ ▲ ▲ BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 4 9 no 0 10 0 0 0 0 1
N N n N N N N BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 4 9 no 0 10 0 0 0 0 1
N N n N N N N BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 4 9 no 0 10 0 0 0 0 1
F F f F F F F BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 4 9 no 0 10 0 0 0 0 1
N N n N N N N BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 4 9 no 0 10 0 0 0 0 1
CH 3 ch C CH CH CH BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 9 no 0 10 0 0 0 0 1
S S s S S S S BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 4 9 no 0 10 0 0 0 0 1
O O o O O O O BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 4 9 no 0 10 0 0 0 0 1
O O o O O O O BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 4 10 no 0 10 0 0 0 0 1
H 3 h H H H H BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 4 10 no 0 10 0 0 0 0 1
OH OH oh O OH OH OH BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 10 no 0 10 0 0 0 0 1
OH OH oh O OH OH OH BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 10 no 0 10 0 0 0 0 1
Ca 2+ ca C Ca Ca Ca BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 10 no 0 10 0 0 0 0 1
O O o O O O O BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 4 10 no 0 3 0 0 0 0 1
O O o O O O O BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 4 10 no 0 10 0 0 0 0 1
b b b b b b b BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 4 10 no 0 10 0 0 0 0 1
OH OH oh O OH OH OH BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 10 no 0 10 0 0 0 0 1
O O o O O O O BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 4 10 no 0 10 0 0 0 0 1
OH OH oh O OH OH OH BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 10 no 0 10 0 0 0 0 1
OH OH oh O OH OH OH BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 10 no 0 10 0 0 0 0 1
O O o O O O O BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 4 10 no 0 10 0 0 0 0 1
O O o O O O O BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 4 10 no 0 10 0 0 0 0 1
O O o O O O O BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 4 10 no 0 10 0 0 0 0 1
S S s S S S S BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 4 10 no 0 5 0 0 0 0 1
CoA CoA coa C Co CoA CoA BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 10 no 0 10 0 0 0 0 1
HMG-CoA reductase hmg-coa H HM HMG HMG- BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 10 - 1 10 0 0 0 0 1
HMG-CoA HMG-CoA hmg-coa H HM HMG HMG- BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 10 - 1 4 0 0 0 0 1
O O o O O O O BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 4 10 no 0 10 0 0 0 0 1
Mevalonate Mevalonate mevalonate M Me Mev Meva BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 10 no 0 10 0 0 0 0 1
2 2 2 2 2 2 2 BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 10 no 0 10 0 0 0 0 1
– – – – – – – BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 4 10 – 1 10 0 0 0 0 1
– – – – – – – BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 4 10 – 1 10 0 0 0 0 1
– – – – – – – BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 4 10 – 1 10 0 0 0 0 1
Rosuvastatin calcium rosuvastatin R Ro Ros Rosu BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 10 no 0 3 0 0 0 0 1
Bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl- Bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl- bis[(e)-7-[4-(4-fluorophenyl)-6-isopropyl- B Bi Bis Bis[ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 10 [()--[-(-)--- 13 7 0 0 0 0 1
2-[methyl(methylsulphonyl)amino] pyrimidin-5-yl] 2-[methyl(methylsulphonyl)amino] 2 2- 2-[ 2-[m BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 10 -[()]--] 8 9 0 0 0 0 1
(3R,5S)-3,5-dihydroxyhept-6-enoic acid] (3r,5s)-3,5-dihydroxyhept-6-enoic ( (3 (3R (3R, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 10 (,)-,---]; 10 10 0 0 0 0 1
(C 22 (c ( (C (C (C BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 10 ();.; 5 8 0 0 0 0 1
CAS registry cas C CA CAS CAS BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 10 :-- 3 6 0 0 0 0 1
a a a a a a a BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 5 11 no 0 10 0 0 0 0 1
Figure 1 figure F Fi Fig Figu BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 11 ., 2 10 0 0 0 0 1
dihydroxy heptenoic dihydroxy d di dih dihy BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 11 ---(-) 6 10 0 0 0 0 1
reductase (the reductase r re red redu BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 11 (- 2 9 0 0 0 0 1
are shown are a ar are are BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 11 ).,- 4 9 0 0 0 0 1
ponding portions ponding p po pon pond BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 11 ,. 2 10 0 0 0 0 1
770 | 770 7 77 770 770 BLOCKSTART PAGESTART NEWFONT LOWERFONT 1 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 0 no 0 10 0 0 0 0 0
www.nature.com/reviews/drugdisc www.nature.com/reviews/drugdisc www.nature.com/reviews/drugdisc w ww www www. BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 ..// 4 10 0 0 0 0 0
The market the T Th The The BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 - 1 9 0 0 0 0 1
the largest the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 . 1 8 0 0 0 0 1
Driven by driven D Dr Dri Driv BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 8 0 0 0 0 1
excess of excess e ex exc exce BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 8 0 0 0 0 1
than US than t th tha than BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 $, 2 9 0 0 0 0 1
by the by b by by by BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 (.). 4 9 0 0 0 0 1
crowded segment crowded c cr cro crow BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 , 1 9 0 0 0 0 1
successful market successful s su suc succ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 . 1 8 0 0 0 0 1
2002, atorvastatin 2002, 2 20 200 2002 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 5 0 , 1 8 0 0 0 0 1
revenues for revenues r re rev reve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 9 0 0 0 0 1
the seven the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 $ 1 8 0 0 0 0 1
and ~US and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 $.,(.). 7 9 0 0 0 0 1
New entrants new N Ne New New BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 8 0 0 0 0 1
face considerable face f fa fac face BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 .- 2 9 0 0 0 0 1
tions for tions t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 , 1 9 0 0 0 0 1
potent of potent p po pot pote BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 , 1 8 0 0 0 0 1
supported by supported s su sup supp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 - 1 9 0 0 0 0 1
mortality data. mortality m mo mor mort BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 ., 2 9 0 0 0 0 1
will soon will w wi wil will BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 5 0 no 0 7 0 0 0 0 1
(including the (including ( (i (in (inc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 (), 3 9 0 0 0 0 1
its greater its i it its its BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 . 1 9 0 0 0 0 1
We predict we W We We We BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 8 0 0 0 0 1
will grow will w wi wil will BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 5 0 $(.). 5 10 0 0 0 0 1
adoption of adoption a ad ado adop BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 '' 2 10 0 0 0 0 1
LDL-C, together ldl-c, L LD LDL LDL- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 0 -, 2 7 0 0 0 0 1
from the from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 8 0 0 0 0 1
Program Adult program P Pr Pro Prog BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 - 1 8 0 0 0 0 1
ing more ing i in ing ing BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 5 0 - 1 8 0 0 0 0 1
modifying therapies, modifying m mo mod modi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 , 1 8 0 0 0 0 1
potent statins. potent p po pot pote BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 .- 2 9 0 0 0 0 1
vastatin are vastatin v va vas vast BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 , 1 9 0 0 0 0 1
must offer must m mu mus must BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 , 1 8 0 0 0 0 1
mortality benefits mortality m mo mor mort BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 8 0 0 0 0 1
agents, without agents, a ag age agen BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 ,. 2 9 0 0 0 0 1
Impact of impact I Im Imp Impa BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 2 no 0 10 0 0 0 0 1
Dose-for-dose, rosuvastatin dose-for-dose, D Do Dos Dose BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 2 --, 3 10 0 0 0 0 1
in lowering in i in in in BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 2 -- 2 9 0 0 0 0 1
levels than levels l le lev leve BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 2 , 1 8 0 0 0 0 1
pravastatin 7 pravastatin p pr pra prav BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 2 ., 2 9 0 0 0 0 1
reported to reported r re rep repo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 2 - 1 9 0 0 0 0 1
to its to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 2 ., 2 9 0 0 0 0 1
efficacy should efficacy e ef eff effi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 2 no 0 8 0 0 0 0 1
rosuvastatin. rosuvastatin. rosuvastatin. r ro ros rosu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 2 . 1 2 0 0 0 0 1
However, the however, H Ho How Howe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 2 , 1 8 0 0 0 0 1
and the and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 2 - 1 8 0 0 0 0 1
domyolysis associated domyolysis d do dom domy BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 2 , 1 9 0 0 0 0 1
in particular in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 2 , 1 9 0 0 0 0 1
the voluntary the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 2 no 0 8 0 0 0 0 1
the NDA the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 2 - 1 8 0 0 0 0 1
a request a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 2 no 0 8 0 0 0 0 1
safety of safety s sa saf safe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 2 .- 2 9 0 0 0 0 1
cerns, considerations cerns, c ce cer cern BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 2 , 1 9 0 0 0 0 1
proteinurea associated proteinurea p pr pro prot BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 2 - 1 8 0 0 0 0 1
of rosuvastatin of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 2 ( 1 9 0 0 0 0 1
label) could label) l la lab labe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 2 ). 2 9 0 0 0 0 1
Until positive until U Un Unt Unti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 2 - 1 9 0 0 0 0 1
data are data d da dat data BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 2 , 1 9 0 0 0 0 1
be restricted be b be be be BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 2 -, 2 9 0 0 0 0 1
unable to unable u un una unab BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 2 no 0 9 0 0 0 0 1
treatments; nevertheless, treatments; t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 2 ;, 2 10 0 0 0 0 1
forecast to forecast f fo for fore BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 2 $.(.). 6 9 0 0 0 0 1
AstraZeneca's pricing astrazeneca's A As Ast Astr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 2 ' 1 8 0 0 0 0 1
the use the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 2 no 0 9 0 0 0 0 1
patients. In patients. p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 2 ., 2 9 0 0 0 0 1
flat-priced at flat-priced f fl fla flat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 2 -$., 4 8 0 0 0 0 1
more expensive more m mo mor more BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 2 -- 2 8 0 0 0 0 1
vastatin, but vastatin, v va vas vast BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 2 , 1 9 0 0 0 0 1
the 20-, the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 2 -,--. 5 5 0 0 0 0 1
In moderately in I In In In BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 7 2 -- 2 7 0 0 0 0 1
terolaemic people, terolaemic t te ter tero BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 2 , 1 9 0 0 0 0 1
of rosuvastatin of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 2 no 0 9 0 0 0 0 1
the 15,000-patient the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 2 ,-( 3 8 0 0 0 0 1
for the for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 2 : 1 9 0 0 0 0 1
an Intervention an a an an an BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 2 ) 1 9 0 0 0 0 1
study, which study, s st stu stud BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 2 ,. 2 8 0 0 0 0 1
Additionally, this additionally, A Ad Add Addi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 5 , 1 10 0 0 0 0 1
of rosuvastatin of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 no 0 8 0 0 0 0 1
risk factors risk r ri ris risk BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 no 0 9 0 0 0 0 1
C-reactive protein c-reactive C C- C-r C-re BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 5 -(). 4 8 0 0 0 0 1
results from results r re res resu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 8 5 , 1 10 0 0 0 0 1
sales of sales s sa sal sale BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 8 5 $. 2 8 0 0 0 0 1
billion in billion b bi bil bill BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 (.). 4 5 0 0 0 0 1
The main the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 5 ' 1 8 0 0 0 0 1
will be will w wi wil will BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 8 5 - 1 9 0 0 0 0 1
bination therapies bination b bi bin bina BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 5 no 0 8 0 0 0 0 1
and Pfizer, and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 ,. 2 9 0 0 0 0 1
a fixed a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 8 5 no 0 8 0 0 0 0 1
the cholesterol the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 no 0 9 0 0 0 0 1
(Zetia; Schering-Plough/Merck) (zetia; ( (Z (Ze (Zet BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 5 (;-/). 6 9 0 0 0 0 1
developing a developing d de dev deve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 - 1 8 0 0 0 0 1
vastatin and vastatin v va vas vast BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 5 no 0 9 0 0 0 0 1
protein (CETP) protein p pr pro prot BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 (). 3 9 0 0 0 0 1
these combinations these t th the thes BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 -, 2 8 0 0 0 0 1
triglyceride and triglyceride t tr tri trig BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 5 - 1 8 0 0 0 0 1
relative to relative r re rel rela BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 . 1 8 0 0 0 0 1
Ultimately, we ultimately, U Ul Ult Ulti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 5 , 1 9 0 0 0 0 1
price, safety price, p pr pri pric BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 ,- 2 8 0 0 0 0 1
lipids such lipids l li lip lipi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 5 -, 2 8 0 0 0 0 1
well as well w we wel well BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 no 0 9 0 0 0 0 1
risk factors risk r ri ris risk BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 no 0 8 0 0 0 0 1
stress, will stress, s st str stre BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 , 1 9 0 0 0 0 1
market dominance. market m ma mar mark BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 . 1 3 0 0 0 0 1
Peter Kirkpatrick peter P Pe Pet Pete BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 1 INITCAP NODIGIT 0 1 0 0 0 0 0 0 9 7 no 0 8 0 0 0 0 1
Discovery. Jeremy discovery. D Di Dis Disc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 7 . 1 9 0 0 0 0 1
at Decision at a at at at BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 7 ,–, 3 10 0 0 0 0 1
London, WC1B london, L Lo Lon Lond BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 7 ,,. 3 4 0 0 0 0 1
Correspondence to correspondence C Co Cor Corr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 7 .. 2 4 0 0 0 0 1
e-mail: jquirk@decisionresources.co.uk e-mail: e e- e-m e-ma BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 7 -:.. 4 7 0 0 0 0 1
doi:10.1038/nrd1205 doi:10.1038/nrd1205 doi:10.1038/nrd1205 d do doi doi: BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 7 :./ 3 10 0 0 0 0 1
1. Tobert, 1. 1 1. 1. 1. BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 7 .,..: 5 8 0 0 0 0 1
HMG-CoA reductase hmg-coa H HM HMG HMG- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 7 -... 4 8 0 0 0 0 1
2, 517–526 2, 2 2, 2, 2, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 7 ,–(). 5 2 0 0 0 0 1
2. Heart 2. 2 2. 2. 2. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 7 ../ 3 8 0 0 0 0 1
Heart Protection heart H He Hea Hear BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 7 no 0 7 0 0 0 0 1
simvastatin in simvastatin s si sim simv BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 7 ,: 2 8 0 0 0 0 1
placebo controlled placebo p pl pla plac BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 7 .,–(). 6 7 0 0 0 0 1
3. Sever, 3. 3 3. 3. 3. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 7 .,... 5 8 0 0 0 0 1
coronary and coronary c co cor coro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 7 no 0 7 0 0 0 0 1
hypertensive patients hypertensive h hy hyp hype BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 7 -- 2 8 0 0 0 0 1
average cholesterol average a av ave aver BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 7 ,- 2 7 0 0 0 0 1
Scandinavian Cardiac scandinavian S Sc Sca Scan BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 7 - 1 8 0 0 0 0 1
(ASCOT-LLA): a (ascot-lla): ( (A (AS (ASC BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 7 (-):. 5 8 0 0 0 0 1
Lancet 361, lancet L La Lan Lanc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 7 ,–(). 5 4 0 0 0 0 1
4. Third 4. 4 4. 4. 4. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 7 . 1 9 0 0 0 0 1
(NCEP) Expert (ncep) ( (N (NC (NCE BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 7 (),, 4 7 0 0 0 0 1
Treatment of treatment T Tr Tre Trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 7 ( 1 8 0 0 0 0 1
Treatment Panel treatment T Tr Tre Trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 7 ).,– 4 9 0 0 0 0 1
(2002). (2002). (2002). ( (2 (20 (200 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 7 (). 3 1 0 0 0 0 1
5. Watanabe, 5. 5 5. 5. 5. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 7 .,.. 4 9 0 0 0 0 1
methanesulfonamide pyrimidine-and methanesulfonamide m me met meth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 7 -- 2 7 0 0 0 0 1
pyrrole-substituted 3,5-dihydroxy-6-heptonates, pyrrole-substituted p py pyr pyrr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 7 -,---, 6 8 0 0 0 0 1
series of series s se ser seri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 7 -... 4 8 0 0 0 0 1
Chem. 5, chem. C Ch Che Chem BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 7 .,–(). 6 3 0 0 0 0 1
6. FDA 6. 6 6. 6. 6. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 7 .[](). 6 8 0 0 0 0 1
<http://www.fda.gov/cder/foi/label/2003/21366_crestor_ <http://www.fda.gov/cder/foi/label/2003/21366_crestor_ <http://www.fda.gov/cder/foi/label/2003/21366_crestor_ < <h <ht <htt BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 1 9 7 ://..///// 10 8 0 0 0 0 1
lbl.pdf> (2003). lbl.pdf> l lb lbl lbl. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 7 .(). 4 2 0 0 0 0 1
7. Jones, 7. 7 7. 7. 7. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 7 .,.... 6 8 0 0 0 0 1
therapies for therapies t th the ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 7 no 0 8 0 0 0 0 1
ranges to ranges r ra ran rang BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 7 :- 2 9 0 0 0 0 1
and high and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 7 .... 4 9 0 0 0 0 1
Cardiol. 92, cardiol. C Ca Car Card BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 7 .,–(). 6 4 0 0 0 0 1
8. Earl, 8. 8 8. 8. 8. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 7 .,.,.... 8 10 0 0 0 0 1
2, 97–98 2, 2 2, 2, 2, BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 7 ,–(). 5 2 0 0 0 0 1
N E n N N N N BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 11 10 no 0 10 0 0 0 0 0
ROSUVASTATIN CALCIUM rosuvastatin R RO ROS ROSU BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 11 10 no 0 10 0 0 0 0 0
9 (29%) 9 9 9 9 9 BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 11 10 () 2 10 0 0 0 0 1
3.5 3.5 3.5 3 3. 3.5 3.5 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 10 . 1 6 0 0 0 0 1
(11%) (11%) (11%) ( (1 (11 (11% BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 10 () 2 10 0 0 0 0 1
4.3 4.3 4.3 4 4. 4.3 4.3 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 10 . 1 6 0 0 0 0 1
(14%) (14%) (14%) ( (1 (14 (14% BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 10 () 2 10 0 0 0 0 1
3 (9%) 3 3 3 3 3 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 11 10 () 2 10 0 0 0 0 1
1.9 (5%) 1.9 1 1. 1.9 1.9 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 10 .() 3 10 0 0 0 0 1
6.6 (21%) 6.6 6 6. 6.6 6.6 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 10 .() 3 10 0 0 0 0 1
3.4 3.4 3.4 3 3. 3.4 3.4 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 10 . 1 6 0 0 0 0 1
(11%) (11%) (11%) ( (1 (11 (11% BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 10 () 2 10 0 0 0 0 1
5.3 (32%) 5.3 5 5. 5.3 5.3 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 10 .() 3 10 0 0 0 0 1
3.6 (20%) 3.6 3 3. 3.6 3.6 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 10 .() 3 10 0 0 0 0 1
1.2 1.2 1.2 1 1. 1.2 1.2 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 10 . 1 8 0 0 0 0 1
(7%) (7%) (7%) ( (7 (7% (7%) BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 10 () 2 10 0 0 0 0 1
7 (41%) 7 7 7 7 7 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 11 10 () 2 10 0 0 0 0 1
5 (21%) 5 5 5 5 5 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 11 11 () 2 10 0 0 0 0 1
1.7 1.7 1.7 1 1. 1.7 1.7 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 11 . 1 8 0 0 0 0 1
(7%) (7%) (7%) ( (7 (7% (7%) BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 11 () 2 10 0 0 0 0 1
2.7 (9%) 2.7 2 2. 2.7 2.7 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 11 .() 3 10 0 0 0 0 1
1.2 (6%) 1.2 1 1. 1.2 1.2 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 11 .() 3 10 0 0 0 0 1
3.1 3.1 3.1 3 3. 3.1 3.1 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 11 . 1 6 0 0 0 0 1
(13%) (13%) (13%) ( (1 (13 (13% BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 11 () 2 10 0 0 0 0 1
1.2 (5%) 1.2 1 1. 1.2 1.2 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 11 .() 3 10 0 0 0 0 1
2007 2007 2007 2 20 200 2007 BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 11 11 no 0 5 0 0 0 0 1
9.5 (39%) 9.5 9 9. 9.5 9.5 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 11 .() 3 10 0 0 0 0 1
Atorvastatin Atorvastatin atorvastatin A At Ato Ator BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 11 no 0 10 0 0 0 0 1
Simvastatin Simvastatin simvastatin S Si Sim Simv BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 11 no 0 10 0 0 0 0 1
Other statins other O Ot Oth Othe BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 11 no 0 10 0 0 0 0 1
Rosuvastatin Rosuvastatin rosuvastatin R Ro Ros Rosu BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 11 no 0 10 0 0 0 0 1
Other lipid-modifying other O Ot Oth Othe BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 11 - 1 10 0 0 0 0 1
Ezetimibe/simvastatin+ezetimibe Ezetimibe/simvastatin+ezetimibe ezetimibe/simvastatin+ezetimibe E Ez Eze Ezet BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 11 / 1 10 0 0 0 0 1
CETP inhibitors cetp C CE CET CETP BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 11 11 no 0 10 0 0 0 0 1
2012 2012 2012 2 20 201 2012 BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 11 11 no 0 10 0 0 0 0 1
2002 2002 2002 2 20 200 2002 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 11 11 no 0 10 0 0 0 0 1
Figure 2 figure F Fi Fig Figu BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 11 $.- 3 9 0 0 0 0 1
include fibrates include i in inc incl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 11 -.(,, 5 10 0 0 0 0 1
Germany, Italy, germany, G Ge Ger Germ BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 11 ,,,,).,. 8 8 0 0 0 0 1